In the present study, we evaluated the effects of IDegLira on GV after switching from a combination of insulin degludec and a DPP-4 inhibitor in hospitalized Japanese patients with T2DM, using CGM. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.